Revelation Biosciences, Inc.
REVB
$0.93
-$0.02-2.04%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.09% | -4.49% | -2.67% | -1.88% | 10.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.44% | -14.92% | -8.62% | -7.87% | 13.22% |
| Operating Income | 3.44% | 14.92% | 8.62% | 7.87% | -13.22% |
| Income Before Tax | 47.61% | 46.78% | -60.79% | -12,400.83% | -1,873.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.61% | 46.78% | -60.79% | -12,400.83% | -1,873.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.61% | 46.78% | -60.79% | -12,400.83% | -1,873.22% |
| EBIT | 3.44% | 14.92% | 8.62% | 7.87% | -13.22% |
| EBITDA | 3.47% | 14.99% | 8.69% | 7.93% | -13.24% |
| EPS Basic | 92.57% | 81.22% | -160.54% | -- | -- |
| Normalized Basic EPS | 93.81% | 82.31% | -160.54% | -- | -- |
| EPS Diluted | 92.57% | 81.22% | -160.54% | -- | -- |
| Normalized Diluted EPS | 93.81% | 82.31% | -160.54% | -- | -- |
| Average Basic Shares Outstanding | 3,351.78% | 2,184.86% | 2,231.28% | -- | -- |
| Average Diluted Shares Outstanding | 3,351.78% | 2,184.86% | 2,231.28% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |